Observational study investigates osimertinib concentrations in non-small cell lung cancer patients, indicating key factors affecting drug levels.
Background: Osimertinib, an EGFR tyrosine kinase inhibitor, is mainly metabolized by CYP3A. This study investigated genetic and non-genetic factors influencing plasma osimertinib concentrations in 36 patients with non-small cell lung cancer. Changes in CYP3A activity were evaluated using its endogenous marker, 4β-hydroxycholesterol (4β-OHC).
No takes yet. Share an insight, caveat, or question.
Yokoyama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: